Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNA HIV-C prime and NYVAC HIV-C boost schedule comparison
ISRCTN20946776Phase 2Completed
- Sponsor
- EuroVacc Foundation
- Start
- Jun 2007
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
01
Overview
Phase 2, randomised, open-label trial of DNA HIV-C and NYVAC HIV-C in human immunodeficiency virus infection (HIV) (2 arms), sponsored by EuroVacc Foundation. Primary endpoints: CD8/CD4+ T-cell response by IFN-gamma ELISPOT at weeks 26 and 28, Grade 3 or above local adverse events and 3 more. Started Jun 2007; status: completed.
02
Drugs
DNA HIV-CNYVAC HIV-C
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ISRCTN20946776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN20946776.